Leerink downgraded Aurinia Pharmaceuticals (AUPH) to Market Perform from Outperform with a $16 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AUPH:
- Aurinia Pharmaceuticals upgraded to Buy from Hold at Jefferies
- Aurinia Pharmaceuticals Reports Strong Q3 2025 Earnings
- Aurinia Pharma’s Earnings Call Highlights Growth and Challenges
- Aurinia downgraded to Sector Perform from Outperform at RBC Capital
- Promising Sales and Market Potential of Lupkynis Drive Buy Rating for Aurinia Pharmaceuticals